01Clinical context
What is the rationale?
Personalisation is limited to clinical rationale, contraindications, interactions, organ function, venous access and monitoring decisions.
Individualised IV Infusion · IV Supportive Treatments · Istanbul
Individualised IV Infusion · IV Supportive Treatments · Istanbul
Individualised IV Infusion
‘Individualised’ does not mean unrestricted mixing, a proprietary formula or guaranteed benefit. A named care method, ingredient or infusion is not a diagnosis and does not establish personal suitability.
Online information cannot diagnose, select an IV product, formula, dose, rate or laboratory protocol, or promise an outcome. Final decisions require an in-person medical assessment.
Clinical Orientation
Finding · identity · evidence · safety
Four questions precede a personal plan.
The sequence prevents a category name from becoming an automatic treatment recommendation.
02Identity
What exactly is proposed?
Each product, licence, manufacturer, batch, compatibility, stability, sterility and preparation responsibility must be explicit; adding many ingredients is not automatically more comprehensive.
03Evidence
What does the evidence support?
Evidence must match each product, route, indication and endpoint rather than the label ‘personalised’.
04Safety
When should it stop?
Stop immediately for breathing difficulty, chest symptoms, swelling, rash, neurological change or a significant infusion-site reaction.
Meaning and Boundary
Intravenous is a route, not a benefit
The category name does not determine the clinical decision.
‘Individualised’ does not mean unrestricted mixing, a proprietary formula or guaranteed benefit.
What assessment may do
- Clarify a limited clinical aim
- Identify the exact method or product
- Compare risks and alternatives
- Set follow-up and stopping criteria
What must not be assumed
- Guarantee suitability or benefit
- Treat IV delivery as automatically superior to oral care
- Create a public personal protocol
- Promise permanence, prevention or a general wellness effect
No remote mixture, prescription, dose, laboratory panel or infusion programme is created.
Medical Suitability
Rationale and organ context before venous access
Five checks come before selection.
History, examination, current treatment, contraindications and a proportionate alternative are reviewed together.
- 01
Clarify the problem
Personalisation is limited to clinical rationale, contraindications, interactions, organ function, venous access and monitoring decisions.
- 02
Review current treatment
Medicines, allergies, previous procedures or infusions and relevant reactions are considered.
- 03
Identify the exact option
Each product, licence, manufacturer, batch, compatibility, stability, sterility and preparation responsibility must be explicit; adding many ingredients is not automatically more comprehensive.
- 04
Compare alternatives
No infusion, oral treatment where appropriate, single-product treatment for a defined indication or diagnosis-led care
- 05
Plan follow-up
Stop immediately for breathing difficulty, chest symptoms, swelling, rash, neurological change or a significant infusion-site reaction.
Infusion Safety Path
Before · during · after
Safety depends on a complete, documented chain.
Each product, licence, manufacturer, batch, compatibility, stability, sterility and preparation responsibility must be explicit; adding many ingredients is not automatically more comprehensive.
01Before
Confirm rationale and product identity
Personalisation is limited to clinical rationale, contraindications, interactions, organ function, venous access and monitoring decisions.
- Review history and examination
- Check contraindications
- Keep alternatives open
02During
Control preparation and administration
Each product, licence, manufacturer, batch, compatibility, stability, sterility and preparation responsibility must be explicit; adding many ingredients is not automatically more comprehensive.
- Maintain traceability
- Monitor tolerance
- Stop when safety changes
03After
Separate expected response from harm
Stop immediately for breathing difficulty, chest symptoms, swelling, rash, neurological change or a significant infusion-site reaction.
- Record observations
- Explain warning signs
- Provide a review route
No public mixture formula, dose, dilution, rate, volume, laboratory panel or infusion schedule is provided.
Evidence and Limits
Method-, product- and indication-specific
Biology or popularity is not proof of clinical benefit.
Evidence must match each product, route, indication and endpoint rather than the label ‘personalised’.
Keep the indication exact
Evidence in one diagnosis or deficiency does not establish a general effect.
Keep the intervention exact
Each product, licence, manufacturer, batch, compatibility, stability, sterility and preparation responsibility must be explicit; adding many ingredients is not automatically more comprehensive.
Keep endpoints separate
Symptoms, photographs, laboratory values and patient-reported outcomes are not interchangeable.
Retain uncertainty
No remote mixture, prescription, dose, laboratory panel or infusion programme is created.
Manufacturer information may identify a product and instructions, but it is not treated as independent evidence of a general class effect.
Individual Plan
Reason · option · review · exit
Personalisation means tighter decisions, not unlimited combinations.
A plan remains limited to a defined question and can conclude that no procedure or infusion is appropriate.
Name the reason
Personalisation is limited to clinical rationale, contraindications, interactions, organ function, venous access and monitoring decisions.
Name the option
Each product, licence, manufacturer, batch, compatibility, stability, sterility and preparation responsibility must be explicit; adding many ingredients is not automatically more comprehensive.
Name the endpoint
Agree what would count as a meaningful and measurable change.
Name the exit
Stop immediately for breathing difficulty, chest symptoms, swelling, rash, neurological change or a significant infusion-site reaction.
Course and Follow-Up
Expected response · complication · reassessment
Repetition is never automatic.
Tolerance and the agreed clinical endpoint are reviewed separately before any further intervention.
- 01Before
Baseline
Record the starting clinical context and intended endpoint.
- 02Same day
Immediate review
Observe tolerance and unexpected reactions.
- 03Later
Clinical review
Compare the relevant finding without automatic attribution.
- 04Decision
Continue, change or stop
Stop immediately for breathing difficulty, chest symptoms, swelling, rash, neurological change or a significant infusion-site reaction.
Risks and Alternatives
Common, serious and delayed harm
Risk remains visible even when a treatment is described as supportive.
Allergy, anaphylaxis, infection, phlebitis, extravasation, fluid or electrolyte disturbance, organ burden and medicine interactions may occur.
01Safety
Recognised harms
Allergy, anaphylaxis, infection, phlebitis, extravasation, fluid or electrolyte disturbance, organ burden and medicine interactions may occur.
02Options
Alternatives
No infusion, oral treatment where appropriate, single-product treatment for a defined indication or diagnosis-led care
03Action
Escalation
Stop immediately for breathing difficulty, chest symptoms, swelling, rash, neurological change or a significant infusion-site reaction.
04Decision
Withhold or stop
Treatment is withheld or stopped when the indication, consent, safety controls or follow-up cannot support a proportionate plan.
Treatment is withheld when diagnosis or rationale, product identity, consent, safety controls or follow-up is inadequate. Stop immediately for breathing difficulty, chest symptoms, swelling, rash, neurological change or a significant infusion-site reaction.
Istanbul and Follow-Up
Assessment and review must travel together
International care needs a workable safety route.
Travel does not shorten observation or remove the need for local medical access.
01Before travel
Organise the question
History and existing records prepare discussion without confirming treatment.
02In Istanbul
Assess in person
Personalisation is limited to clinical rationale, contraindications, interactions, organ function, venous access and monitoring decisions.
03Treatment day
Keep exact records
Each product, licence, manufacturer, batch, compatibility, stability, sterility and preparation responsibility must be explicit; adding many ingredients is not automatically more comprehensive.
04After return
Plan escalation
Stop immediately for breathing difficulty, chest symptoms, swelling, rash, neurological change or a significant infusion-site reaction.
The Doctor Aslan Approach
Clinical question before treatment label
Selection follows diagnosis, identity, evidence and safety.
Doctor Aslan keeps the clinical question, exact intervention, realistic limits, alternatives and follow-up in the same decision.
Assess first
Personalisation is limited to clinical rationale, contraindications, interactions, organ function, venous access and monitoring decisions.
Verify identity
Each product, licence, manufacturer, batch, compatibility, stability, sterility and preparation responsibility must be explicit; adding many ingredients is not automatically more comprehensive.
Limit the claim
No remote mixture, prescription, dose, laboratory panel or infusion programme is created.
Accept no treatment
Observation or another established pathway may be the safer choice.
Medical responsibility: Dr İsmail AslanMedical review: 24 August 2026General patient information about Individualised IV Infusion; no personal prescription or outcome guarantee
Frequently Asked Questions
Short and clear
Questions commonly asked before a decision.
These answers provide general orientation and do not replace personal diagnosis or treatment planning.
01What is Individualised IV Infusion?+
Individualised IV Infusion is described on this page as one defined clinical route. Its role, limits and possible alternatives are considered together rather than treating the method name as a personal recommendation.
02Who may be assessed for Individualised IV Infusion?+
Suitability depends on the medical question, history, examination, the exact product or device where relevant, realistic aims and an individual benefit–risk assessment.
03What remains undecided after an online review?+
Diagnosis, definitive suitability, the treatment protocol, product, dose or device settings, expected response and the option not to proceed remain subject to personal medical assessment.
04How are treatment and follow-up in Istanbul planned?+
The in-person examination remains the decision point. Expected early reactions, warning signs, the direct contact route, return travel and access to appropriate local medical care are discussed before treatment.
Next Step
Define the question · verify the option · compare alternatives